×
Entrez Id:
3106
Gene Symbol:
HLA-B
HLA-B
0.100
GeneticVariation
group
GWASCAT
An extended genome-wide association study identifies novel susceptibility loci for nasopharyngeal carcinoma.
27436580
2016
LINC02571
0.100
GeneticVariation
group
GWASCAT
An extended genome-wide association study identifies novel susceptibility loci for nasopharyngeal carcinoma.
27436580
2016
×
Entrez Id:
3265
Gene Symbol:
HRAS
HRAS
0.100
GeneticVariation
group
CLINVAR
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.
26619011
2016
×
Entrez Id:
3105
Gene Symbol:
HLA-A
HLA-A
0.100
GeneticVariation
group
GWASCAT
An extended genome-wide association study identifies novel susceptibility loci for nasopharyngeal carcinoma.
27436580
2016
×
Entrez Id:
4893
Gene Symbol:
NRAS
NRAS
0.100
GeneticVariation
group
CLINVAR
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.
26619011
2016
CDKN2B-AS1
0.100
GeneticVariation
group
GWASCAT
A genome-wide association study of nasopharyngeal carcinoma identifies three new susceptibility loci.
20512145
2010
×
Entrez Id:
3106
Gene Symbol:
HLA-B
HLA-B
0.100
GeneticVariation
group
GWASCAT
A genome-wide association study of nasopharyngeal carcinoma identifies three new susceptibility loci.
20512145
2010
LINC02571
0.100
GeneticVariation
group
GWASCAT
A genome-wide association study of nasopharyngeal carcinoma identifies three new susceptibility loci.
20512145
2010
×
Entrez Id:
3105
Gene Symbol:
HLA-A
HLA-A
0.100
GeneticVariation
group
GWASCAT
A genome-wide association study of nasopharyngeal carcinoma identifies three new susceptibility loci.
20512145
2010
×
Entrez Id:
3680
Gene Symbol:
ITGA9
ITGA9
0.100
GeneticVariation
group
GWASCAT
A genome-wide association study identifies ITGA9 conferring risk of nasopharyngeal carcinoma.
19478819
2009
×
Entrez Id:
3105
Gene Symbol:
HLA-A
HLA-A
0.100
GeneticVariation
group
GWASCAT
Genome-wide association study reveals multiple nasopharyngeal carcinoma-associated loci within the HLA region at chromosome 6p21.3.
19664746
2009
×
Entrez Id:
4486
Gene Symbol:
MST1R
MST1R
0.100
Biomarker
group
HPO
×
Entrez Id:
79728
Gene Symbol:
PALB2
PALB2
0.100
CausalMutation
group
CLINVAR
×
Entrez Id:
2067
Gene Symbol:
ERCC1
ERCC1
0.010
AlteredExpression
group
BEFREE
Immunohistochemical analysis was used to assess the ERCC1 expression in nasopharyngeal tumor tissues.
29578165
2018
×
Entrez Id:
3605
Gene Symbol:
IL17A
IL17A
0.010
AlteredExpression
group
BEFREE
Expression of miR-135a in the cancer cells isolated from nasopharyngeal tumors was significantly lower than that in NP69 cells, and suppression of IL-17 by miR-135a mimic resulted in significant inhibition of NPC cell proliferation.
29734196
2018
×
Entrez Id:
6422
Gene Symbol:
SFRP1
SFRP1
0.010
PosttranslationalModification
group
BEFREE
KL and SFRP1 methylation were more predominant in nasopharyngeal tumors (P = 0.001 and P = 0.031 respectively).
28812223
2017
×
Entrez Id:
57016
Gene Symbol:
AKR1B10
AKR1B10
0.010
AlteredExpression
group
BEFREE
To examine the expression of AKR1B10 at mRNA and protein levels in nasopharyngeal tumors and correlate its expression with clinicopathological parameters.
26835713
2016
×
Entrez Id:
6774
Gene Symbol:
STAT3
STAT3
0.010
Biomarker
group
BEFREE
EGCG inhibits the growth and tumorigenicity of nasopharyngeal tumor -initiating cells through attenuation of STAT3 activation.
24966947
2014
×
Entrez Id:
83596
Gene Symbol:
BCL2L12
BCL2L12
0.010
AlteredExpression
group
BEFREE
Higher BCL2L12 mRNA levels were detected in undifferentiated carcinomas of the nasopharynx, rather than in nonkeratinizing nasopharyngeal tumors (P = 0.045).
21152697
2011
×
Entrez Id:
596
Gene Symbol:
BCL2
BCL2
0.010
Biomarker
group
BEFREE
Survival analysis demonstrated that patients with BCL2 -positive nasopharyngeal tumors have significantly shorter disease-free and overall survival (p = 0.011 and p = 0.028, respectively).
20514538
2010
×
Entrez Id:
2064
Gene Symbol:
ERBB2
ERBB2
0.010
GeneticVariation
group
BEFREE
Increase of the therapeutic effect by treating nasopharyngeal tumor with combination of HER-2 siRNA and paclitaxel.
20198351
2010
×
Entrez Id:
3082
Gene Symbol:
HGF
HGF
0.010
Biomarker
group
LHGDN
Hepatocyte growth factor enhances proteolysis and invasiveness of human nasopharyngeal cancer cells through activation of PI3K and JNK.
18789327
2008
×
Entrez Id:
308
Gene Symbol:
ANXA5
ANXA5
0.010
AlteredExpression
group
LHGDN
Proteomic comparison of nasopharyngeal cancer cell lines C666-1 and NP69 identifies down-regulation of annexin II and beta2-tubulin for nasopharyngeal carcinoma.
18384219
2008
×
Entrez Id:
5216
Gene Symbol:
PFN1
PFN1
0.010
AlteredExpression
group
LHGDN
Proteomic comparison of nasopharyngeal cancer cell lines C666-1 and NP69 identifies down-regulation of annexin II and beta2-tubulin for nasopharyngeal carcinoma.
18384219
2008
×
Entrez Id:
2697
Gene Symbol:
GJA1
GJA1
0.010
AlteredExpression
group
BEFREE
Thus, the amplified Cx43 expression by an antitumor agent, an HDAC inhibitor, may have great potential as a growth inhibitor for nasopharyngeal tumors .
17487363
2007